Literature DB >> 23041317

A truncated form of IKKα is responsible for specific nuclear IKK activity in colorectal cancer.

Pol Margalef1, Vanessa Fernández-Majada, Alberto Villanueva, Ricard Garcia-Carbonell, Mar Iglesias, Laura López, María Martínez-Iniesta, Jordi Villà-Freixa, Mari Carmen Mulero, Montserrat Andreu, Ferran Torres, Marty W Mayo, Anna Bigas, Lluis Espinosa.   

Abstract

Nuclear IKKα regulates gene transcription by phosphorylating specific substrates and has been linked to cancer progression and metastasis. However, the mechanistic connection between tumorigenesis and IKKα activity remains poorly understood. We have now analyzed 288 human colorectal cancer samples and found a significant association between the presence of nuclear IKK and malignancy. Importantly, the nucleus of tumor cells contains an active IKKα isoform with a predicted molecular weight of 45 kDa (p45-IKKα) that includes the kinase domain but lacks several regulatory regions. Active nuclear p45-IKKα forms a complex with nonactive IKKα and NEMO that mediates phosphorylation of SMRT and histone H3. Proteolytic cleavage of FL-IKKα into p45-IKKα is required for preventing the apoptosis of CRC cells in vitro and sustaining tumor growth in vivo. Our findings identify a potentially druggable target for treating patients with advance refractory CRC.
Copyright © 2012 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041317     DOI: 10.1016/j.celrep.2012.08.028

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  17 in total

1.  The relationship between members of the canonical NF-kB pathway, tumour microenvironment and cancer specific survival in colorectal cancer patients.

Authors:  Jean A Quinn; Lindsay Bennett; Meera Patel; Mikaela Frixou; James H Park; Antonia Roseweir; Paul G Horgan; Donald C McMillan; Joanne Edwards
Journal:  Histol Histopathol       Date:  2019-10-08       Impact factor: 2.303

Review 2.  Targeting IκappaB kinases for cancer therapy.

Authors:  Nikee Awasthee; Vipin Rai; Srinivas Chava; Palanisamy Nallasamy; Ajaikumar B Kunnumakkara; Anupam Bishayee; Subhash C Chauhan; Kishore B Challagundla; Subash C Gupta
Journal:  Semin Cancer Biol       Date:  2018-02-24       Impact factor: 15.707

Review 3.  The IκB kinase complex in NF-κB regulation and beyond.

Authors:  Michael Hinz; Claus Scheidereit
Journal:  EMBO Rep       Date:  2013-12-27       Impact factor: 8.807

4.  A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1.

Authors:  Dror Hollander; Maya Donyo; Nir Atias; Keren Mekahel; Zeev Melamed; Sivan Yannai; Galit Lev-Maor; Asaf Shilo; Schraga Schwartz; Iris Barshack; Roded Sharan; Gil Ast
Journal:  Genome Res       Date:  2016-02-09       Impact factor: 9.043

5.  Endosomal acidification inhibitors for the treatment of BRAF mutant tumors.

Authors:  Lluís Espinosa
Journal:  Mol Cell Oncol       Date:  2015-11-18

6.  IKKα is required in the intestinal epithelial cells for tumour stemness.

Authors:  Carlota Colomer; Pol Margalef; Jessica Gonzalez; Anna Vert; Anna Bigas; Lluis Espinosa
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640

Review 7.  NF-κB Members Left Home: NF-κB-Independent Roles in Cancer.

Authors:  Carlota Colomer; Laura Marruecos; Anna Vert; Anna Bigas; Lluis Espinosa
Journal:  Biomedicines       Date:  2017-05-25

8.  Transplantation from a symptomatic carrier sister restores host defenses but does not prevent colitis in NEMO deficiency.

Authors:  Christian Klemann; Ulrich Pannicke; Deborah J Morris-Rosendahl; Katerina Vlantis; Marta Rizzi; Holm Uhlig; Thomas Vraetz; Carsten Speckmann; Brigitte Strahm; Manolis Pasparakis; Klaus Schwarz; Stephan Ehl; Jan C Rohr
Journal:  Clin Immunol       Date:  2016-01-23       Impact factor: 3.969

9.  IKKα promotes intestinal tumorigenesis by limiting recruitment of M1-like polarized myeloid cells.

Authors:  Serkan I Göktuna; Ozge Canli; Julia Bollrath; Alexander A Fingerle; David Horst; Michaela A Diamanti; Charles Pallangyo; Moritz Bennecke; Tim Nebelsiek; Arun K Mankan; Roland Lang; David Artis; Yinling Hu; Thomas Patzelt; Jürgen Ruland; Thomas Kirchner; M Mark Taketo; Alain Chariot; Melek C Arkan; Florian R Greten
Journal:  Cell Rep       Date:  2014-05-29       Impact factor: 9.423

Review 10.  Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.

Authors:  Andrew Paul; Joanne Edwards; Christopher Pepper; Simon Mackay
Journal:  Cells       Date:  2018-10-20       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.